First Time Use of SD-809 in Huntington Disease
Public ClinicalTrials.gov record NCT01795859. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease
Study identification
- NCT ID
- NCT01795859
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Enrollment
- 90 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- SD-809 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 4, 2013
- Primary completion
- Dec 4, 2014
- Completion
- Dec 4, 2014
- Last update posted
- Sep 19, 2017
2013 – 2014
United States locations
- U.S. sites
- 37
- U.S. states
- 27
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 057 | Birmingham | Alabama | — | — |
| Teva Investigational Site 038 | Phoenix | Arizona | — | — |
| Teva Investigational Site 298 | Fayetteville | Arkansas | — | — |
| Teva Investigational Site 050 | Los Angeles | California | — | — |
| Teva Investigational Site 052 | Englewood | Colorado | — | — |
| Teva Investigational Site 333 | Washington D.C. | District of Columbia | — | — |
| Teva Investigational Site 196 | Boca Raton | Florida | — | — |
| Teva Investigational Site 160 | Gainesville | Florida | — | — |
| Teva Investigational Site 014 | Miami | Florida | — | — |
| Teva Investigational Site 032 | Atlanta | Georgia | — | — |
| Teva Investigational Site 045 | Indianapolis | Indiana | — | — |
| Teva Investigational Site 024 | Iowa City | Iowa | — | — |
| Teva Investigational Site 029 | Kansas City | Kansas | — | — |
| Teva Investigational Site 083 | Wichita | Kansas | — | — |
| Teva Investigational Site 087 | Louisville | Kentucky | — | — |
| Teva Investigational Site 028 | Baltimore | Maryland | — | — |
| Teva Investigational Site 040 | Boston | Massachusetts | — | — |
| Teva Investigational Site 027 | St Louis | Missouri | — | — |
| Teva Investigational Site 194 | Las Vegas | Nevada | — | — |
| Teva Investigational Site 328 | Camden | New Jersey | — | — |
| Teva Investigational Site 026 | New Brunswick | New Jersey | — | — |
| Teva Investigational Site 037 | Albany | New York | — | — |
| Teva Investigational Site 002 | New York | New York | — | — |
| Teva Investigational Site 342 | Patchogue | New York | — | — |
| Teva Investigational Site 119 | Durham | North Carolina | — | — |
| Teva Investigational Site 089 | Cincinnati | Ohio | — | — |
| Teva Investigational Site 020 | Columbus | Ohio | — | — |
| Teva Investigational Site 093 | Toledo | Ohio | — | — |
| Teva Investigational Site 341 | Tulsa | Oklahoma | — | — |
| Teva Investigational Site 031 | Nashville | Tennessee | — | — |
| Teva Investigational Site 007 | Houston | Texas | — | — |
| Teva Investigational Site 199 | Houston | Texas | — | — |
| Teva Investigational Site 100 | Salt Lake City | Utah | — | — |
| Teva Investigational Site 137 | Burlington | Vermont | — | — |
| Teva Investigational Site 220 | Kirkland | Washington | — | — |
| Teva Investigational Site 096 | Seattle | Washington | — | — |
| Teva Investigational Site 104 | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01795859, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 19, 2017 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01795859 live on ClinicalTrials.gov.